OrthoPediatrics (KIDS) Expected to Announce Earnings on Thursday

OrthoPediatrics (NASDAQ:KIDS) is anticipated to post its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect OrthoPediatrics to post earnings of ($0.29) per share and revenue of $61.2720 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

OrthoPediatrics Stock Up 0.2%

Shares of NASDAQ:KIDS opened at $17.09 on Thursday. The firm’s 50 day moving average price is $17.71 and its 200 day moving average price is $18.25. The stock has a market cap of $428.62 million, a price-to-earnings ratio of -8.76 and a beta of 1.12. OrthoPediatrics has a fifty-two week low of $15.28 and a fifty-two week high of $26.40. The company has a quick ratio of 3.52, a current ratio of 7.40 and a debt-to-equity ratio of 0.28.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Invesco Ltd. lifted its position in OrthoPediatrics by 22.5% during the 2nd quarter. Invesco Ltd. now owns 22,482 shares of the company’s stock worth $483,000 after acquiring an additional 4,133 shares during the period. American Century Companies Inc. lifted its holdings in shares of OrthoPediatrics by 12.5% during the second quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock worth $741,000 after purchasing an additional 3,828 shares during the period. Jane Street Group LLC acquired a new stake in shares of OrthoPediatrics during the first quarter worth $389,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after buying an additional 645 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in OrthoPediatrics in the 4th quarter valued at $188,000. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

KIDS has been the subject of several recent analyst reports. BTIG Research reaffirmed a “buy” rating and set a $23.00 price objective on shares of OrthoPediatrics in a research report on Wednesday, October 29th. Canaccord Genuity Group started coverage on OrthoPediatrics in a report on Wednesday, December 10th. They set a “buy” rating and a $24.00 price target for the company. Wall Street Zen raised OrthoPediatrics from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd. Finally, Needham & Company LLC lowered their price target on OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $23.89.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.